MBCL-43. RECURRENT MEDULLOBLASTOMA – LONG-TERM SURVIVAL WITH A “MEMMAT” BASED ANTIANGIOGENIC APPROACH

INTRODUCTION: Patients with recurrent medulloblastoma have a poor prognosis with only around 8% of patients surviving at 5 years irrespective of salvage therapy used. We report on 29 patients from four institutions treated with a “MEMMAT” based antiangiogenic combination therapy. PATIENTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Slavc, Irene, Peyrl, Andreas, Gojo, Johannes, Holm, Stefan, Blomgren, Klas, Sehested, Astrid M, Leblond, Pierre, Czech, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Medulloblastoma (Clinical)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715695/
http://dx.doi.org/10.1093/neuonc/noaa222.516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715695/
http://dx.doi.org/10.1093/neuonc/noaa222.516

Ejemplares similares